- Home
- COCP
as of 03-19-2026 10:35am EST
Cocrystal Pharma Inc is a biotechnology company discovering and developing novel antiviral therapeutics that target the replication machinery of influenza viruses, hepatitis C viruses, and noroviruses. It employs structure-based technologies and Nobel Prize-winning expertise to create first and in-class antiviral drugs. It is developing CC-31244, an investigational, oral, broad-spectrum replication inhibitor called a non-nucleoside inhibitor (NNI).
| Founded: | 2006 | Country: | United States |
| Employees: | N/A | City: | BOTHELL |
| Market Cap: | 15.3M | IPO Year: | 2011 |
| Target Price: | $6.00 | AVG Volume (30 days): | 41.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.61 | EPS Growth: | 8.02 |
| 52 Week Low/High: | $0.86 - $2.19 | Next Earning Date: | 03-27-2026 |
| Revenue: | $12,712,091 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -1.82 | Index: | N/A |
| Free Cash Flow: | -16493000.0 | FCF Growth: | N/A |
AI-Powered COCP Daily Prediction
Machine learning model trained on 25+ technical indicators
AI Recommendation
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Cocrystal Pharma Inc. (COCP)
Director, 10% Owner
Avg Cost/Share
$1.00
Shares
20,000
Total Value
$19,952.00
Owned After
1,908,551
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$0.95
Shares
50,000
Total Value
$47,280.00
Owned After
1,908,551
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$0.95
Shares
50,000
Total Value
$47,275.00
Owned After
1,908,551
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$0.97
Shares
20,000
Total Value
$19,310.00
Owned After
1,908,551
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$0.97
Shares
40,000
Total Value
$38,944.00
Owned After
1,908,551
SEC Form 4
Director, 10% Owner
Avg Cost/Share
$0.97
Shares
25,000
Total Value
$24,257.50
Owned After
1,908,551
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| FROST PHILLIP MD ET AL | COCP | Director, 10% Owner | Feb 24, 2026 | Buy | $1.00 | 20,000 | $19,952.00 | 1,908,551 | |
| FROST PHILLIP MD ET AL | COCP | Director, 10% Owner | Feb 6, 2026 | Buy | $0.95 | 50,000 | $47,280.00 | 1,908,551 | |
| FROST PHILLIP MD ET AL | COCP | Director, 10% Owner | Dec 31, 2025 | Buy | $0.95 | 50,000 | $47,275.00 | 1,908,551 | |
| FROST PHILLIP MD ET AL | COCP | Director, 10% Owner | Dec 30, 2025 | Buy | $0.97 | 20,000 | $19,310.00 | 1,908,551 | |
| FROST PHILLIP MD ET AL | COCP | Director, 10% Owner | Dec 26, 2025 | Buy | $0.97 | 40,000 | $38,944.00 | 1,908,551 | |
| FROST PHILLIP MD ET AL | COCP | Director, 10% Owner | Dec 24, 2025 | Buy | $0.97 | 25,000 | $24,257.50 | 1,908,551 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q3 Q3 2025 Earnings
8-K SELL Nov 14, 2025 · 100% conf.
Q3 2025 Earnings
8-K SELLNov 14, 2025 · 100% conf.
1D
-3.31%
$1.00
Act: -0.97%
5D
-8.39%
$0.94
Act: -11.35%
20D
-6.95%
$0.96
false 0001412486
0001412486
2025-11-14 2025-11-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 14, 2025
Cocrystal Pharma, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-38418
35-2528215
(State or other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS
Employer
Identification No.)
19805 N. Creek Parkway
Bothell, WA
98011
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (877) 262-7123
(Former name or former address, if changed since last report.): n/a
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
COCP
The Nasdaq Stock Market, LLC
(The Nasdaq Capital Market)
Item 2.02 Results of Operations and Financial Condition
On November 14, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended September 30, 2025 and providing certain business updates. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Item 2.02, and Exhibit 99.1 attached hereto, shall not be deemed “filed” for the purposes of or otherwise subject to the liabilities under Section 18 of the Securities Exchange Act of 1934, as amended. Unless expressly incorporated into a filing of the Company under the Securities Act of 1933, as amended, or the Exchange Act, the information contained in this Item 2.02 and Exhibit 99.1 hereto shall not be incorporated by reference into any Company filing, whether made before or after the date hereof, regardless of any general incorporation language in such filing
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit
Description
99.1
Press Release dated November 14, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cocrystal Pharma, Inc.
Date: November 14, 2025 By: /s/ James Martin
Name: James Martin
Title: Co-Chief Executive Officer and Chief Financial Officer
2025 Q2 Q2 2025 Earnings
8-K Aug 14, 2025
Q2 2025 Earnings
8-KAug 14, 2025
false 0001412486
0001412486
2025-08-14 2025-08-14
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 14, 2025
Cocrystal Pharma, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-38418
35-2528215
(State or other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS
Employer
Identification No.)
19805 N. Creek Parkway
Bothell, WA
98011
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (877) 262-7123
(Former name or former address, if changed since last report.): n/a
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
COCP
The Nasdaq Stock Market LLC
(The Nasdaq Capital Market)
Item 2.02 Results of Operations and Financial Condition
On August 14, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore, the information contained in this Item 2.02 or Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit
Description
99.1
Press Release dated August 14, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cocrystal Pharma, Inc.
Date: August 14, 2025 By: /s/ James Martin
Name: James Martin
Title: Chief Financial Officer and Co-Chief Executive Officer
2025 Q1 Q1 2025 Earnings
8-K May 15, 2025
Q1 2025 Earnings
8-KMay 15, 2025
false 0001412486
0001412486
2025-05-15 2025-05-15
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): May 15, 2025
Cocrystal Pharma, Inc.
(Exact name of registrant as specified in its charter)
Delaware
001-38418
35-2528215
(State or other Jurisdiction
of Incorporation)
(Commission
File Number)
(IRS Employer
Identification No.)
19805 N. Creek Parkway
Bothell, WA
98011
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code: (877) 262-7123
(Former name or former address, if changed since last report.): n/a
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Securities registered pursuant to Section 12(b) of the Act:
Title of Each Class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock
COCP
The Nasdaq Stock Market LLC
(The Nasdaq Capital Market)
Item 2.02 Results of Operations and Financial Condition
On May 15, 2025, Cocrystal Pharma, Inc. (the “Company”) issued a press release announcing its results of operations for the fiscal quarter ended March 31, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information contained in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, or otherwise subject to the liabilities of that section. Furthermore, the information contained in this Item 2.02 or Exhibit 99.1 shall not be deemed to be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, except as shall be expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
Exhibit
Description
99.1
Press Release dated May 15, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Cocrystal Pharma, Inc.
Date: May 15, 2025 By: /s/ James Martin
Name: James Martin
Title: Chief Financial Officer and Co-Chief Executive Officer
Compare COCP vs Leading Stocks
See how COCP stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "COCP Cocrystal Pharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.